Most Chinese biotechnology stocks have been in a downward channel but not SSRX. This stock has been in an upward channel since last September, which means it moved more with the U.S. market rather than the Chinese pharmaceutical market over the past eight months. The stock saw strong volume come in all this week especially on Thursday in which SSRX almost reached a 52-week high. On Friday, Oppenheimer said the Chinese biotech/pharma space was a buying opportunity on recent weakness and outlined that buying should move first into the leader of the sector - that would be SSRX.
Click to enlarge
Price Target: $19.00
Support: $16.92
http://seekingalpha.com/article/265251-looking-ahead-to-the-trading-week-stocks-and-charts-to-watch?source=yahoo
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM